Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40


Systematic review of drug administration costs and implications for biopharmaceutical manufacturing.

Tetteh E, Morris S.

Appl Health Econ Health Policy. 2013 Oct;11(5):445-56. doi: 10.1007/s40258-013-0045-x. Review.


Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.

Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF.

Health Technol Assess. 2010 Dec;14(54):iii-iv, ix-xi, 1-141. doi: 10.3310/hta14540. Review.


The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.


The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.


The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model.

Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R.

Health Technol Assess. 2009 Aug;13(38):iii-iv, xi-xiv, 1-156. doi: 10.3310/hta13380. Review.


Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.


Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.


Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, Lühmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.


The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A.

Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190. Review.


Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.


Generalisability in economic evaluation studies in healthcare: a review and case studies.

Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.

Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. Review.


The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.


A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.

Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A.

Appl Health Econ Health Policy. 2013 Feb;11(1):27-43. doi: 10.1007/s40258-012-0001-1. Review.


Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Prince FH, van Suijlekom-Smit LW.

Paediatr Drugs. 2013 Aug;15(4):271-80. doi: 10.1007/s40272-013-0023-7.


Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.


Potential use of routine databases in health technology assessment.

Raftery J, Roderick P, Stevens A.

Health Technol Assess. 2005 May;9(20):1-92, iii-iv. Review.


The impact of the profile of biologics on treatment costs.

Leardini G, Rigon C.

Autoimmun Rev. 2013 Jun;12(8):842-7. doi: 10.1016/j.autrev.2012.11.011. Epub 2012 Dec 3. Review.


Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.


Over-, under- and misuse of pain treatment in Germany.

Dietl M, Korczak D.

GMS Health Technol Assess. 2011 Apr 19;7:Doc03. doi: 10.3205/hta000094.

Supplemental Content

Support Center